This is a working overview of clinical evidence, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-01. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
In broiler chickens, the use of lithium ascorbate from the 14th to the 42nd day of cultivation in the amount of 1, 5, 10 mg/kg of body weight increased the total protein in blood serum due to the increase in the globulin fraction, which indicates an increase in the protective functions of the body of chicken and is one of reasons for higher livestock safety (P<0.05). Lithium ascorbate was tested as a cerebroprotective agent in the model of ischemic stroke. The effect of lithium ascorbate was studied on a model of chronic alcohol intoxication, in which deviant behavior of animals is combined with irreversible degenerative changes in the liver and central nervous system (including demyelination of nerves). Lithium ascorbate at doses of 5, 10 and 30 mg/kg normalized behavioral responses in the open field and elevated plus maze tests. An increase in the dose of lithium ascorbate (10 mg/kg, 30 mg/kg) did not lead to a significant improvement in the studied parameters of the condition. Histological analysis showed that the use of lithium ascorbate minimized the level of ischemic damage to neurocytes to the level of a reversible state and contributed to the preservation of the myelin sheaths of nerves.
== Adverse effects == The adverse side effects of amphetamine are many and varied, and the amount of amphetamine used is the primary factor in determining the likelihood and severity of adverse effects. Amphetamine products such as Adderall, Vyvanse, and their generic equivalents are currently approved by the U.S. FDA for long-term therapeutic use. Recreational use of amphetamine generally involves much larger doses, which have a greater risk of serious adverse drug effects than dosages used for therapeutic purposes.
Condensation reactions likely played major roles in the synthesis of the first biotic molecules including early peptides and nucleic acids. In fact, condensation reactions would be required at multiple steps in RNA oligomerization: the condensation of nucleobases and sugars, nucleoside phosphorylation, and nucleotide polymerization.
Sources: en.wikipedia.org
== External links == "Zanidatamab-hrii". NCI Drug Dictionary. "Zanidatamab (Code C130010)". NCI Thesaurus. Archived from the original on 16 April 2025. Clinical trial number NCT04466891 for "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01)" at ClinicalTrials.gov
== Common Bioconjugation Reactions == Synthesis of bioconjugates involves a variety of challenges, ranging from the simple and nonspecific use of a fluorescent dye marker to the complex design of antibody drug conjugates. Various bioconjugation reactions have been developed to chemically modify proteins. Common types of bioconjugation reactions on proteins are coupling to lysine, cysteine, and tyrosine amino acid residues, as well as modification of tryptophan residues and of the N- and C- terminus. However, these reactions often lack chemoselectivity and efficiency, because they depend on the presence of native amino acids, which are present in large quantities that hinder selectivity. There is an increasing need for chemical strategies that can effectively attach synthetic molecules site specifically to proteins. One strategy is to first install a unique functional group onto a protein, and then a bioorthogonal reaction is used to couple a biomolecule with this unique functional group. The bioorthogonal reactions targeting non-native functional groups are widely used in bioconjugation chemistry. Some important reactions are modification of ketone and aldehydes, Staudinger ligation with organic azides, copper-catalyzed Huisgen cycloaddition of azides, and strain promoted Huisgen cycloaddition of azides. Bioconjugation reactions would ideally possess the criteria of easy access to the components for reaction, high yield, high rate constant, wide tolerance of reaction conditions, and applicability in diverse contexts.
Le Havre is the birthplace of many musicians and composers such as Henri Woollett (1864–1936), André Caplet (1878–1925) and Arthur Honegger (1892–1955). There was also Victor Mustel (1815–1890) who was famous for having perfected the harmonium. Le Havre has long been regarded as one of the cradles of French rock and blues. In the 1980s many groups have emerged after a first dynamic development in the 1960s and 1970s. The most famous personality of Le Havre rock is Little Bob who began his career in the 1970s. The port tradition in many of the groups was repeated in the unused sheds of the port, such as Bovis hall which could hold 20,000 spectators. A blues festival, driven by Jean-François Skrobek, Blues a Gogo existed for eight years from 1995 to 2002. Several artists have been produced such as: Youssou N'Dour, Popa Chubby, Amadou & Mariam, Patrick Verbeke etc. It was organized by the Coup de Bleu association whose former president was head of music Café L'Agora in the Niemeyer Centre which produced the new Le Havre scene. During these same years, the Festival of the Future, the local version of the Fête de l'Humanité (Festival of Humanity), attracted a large audience. Currently, the musical tradition continues in the Symphony Orchestra of the city of Le Havre, the orchestra of Concerts André Caplet, the conservatory, and music schools such as the Centre for Vocal and Musical Expression (rock) or the JUPO (mainly jazz), associations or labels like Papa's Production (la Folie Ordinaire, Mob's et Travaux, Dominique Comont, Souinq, Your Happy End etc.).
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.